Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.44 |
| ▸ | MPI | P34949 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4933891 | 0.91 | ALDH1A1 (0.68) | ALDH1A1MAPK1POLBSMN1; SMN2MAPT | |
| SCHEMBL8188113 | 0.85 | ALDH1A1 (0.52) | ALDH1A1MAPK1POLBSMN1; SMN2MAPT | |
| SCHEMBL10711429 | 0.83 | ALDH1A1 (0.55) | ALDH1A1MAPK1POLBSMN1; SMN2MAPT | |
| SCHEMBL16663489 | 0.79 | ALDH1A1 (0.68) | ALDH1A1MAPK1POLBSMN1; SMN2MAPT | |
| SCHEMBL10532585 | 0.79 | ALDH1A1 (0.75) | ALDH1A1MAPK1POLBSMN1; SMN2MAPT | |
| SCHEMBL1522436 | 0.79 | ALDH1A1 (0.56) | ALDH1A1MAPK1POLBSMN1; SMN2MAPT | |
| SCHEMBL31464158 | 0.76 | ALDH1A1 (0.48) | ALDH1A1MAPK1POLBSMN1; SMN2MAPT | |
| SCHEMBL31464156 | 0.76 | ALDH1A1 (0.48) | ALDH1A1MAPK1POLBSMN1; SMN2MAPT | |
| SCHEMBL13369154 | 0.75 | ALDH1A1 (0.69) | ALDH1A1MAPK1POLBSMN1; SMN2MAPT | |
| SCHEMBL14697944 | 0.75 | ALDH1A1 (0.74) | ALDH1A1MAPK1POLBSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-2139887-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | Alantos Pharmaceuticals Holding, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| WO-2008109180-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109180-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | ALDH1A1 714/4885MAPK1 1825/4885POLB 2906/4885 |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | ALDH1A1 1871/4885MAPK1 2672/4885POLB 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.